Status:
COMPLETED
Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema
Lead Sponsor:
Augenabteilung Allgemeines Krankenhaus Linz
Conditions:
Age Related Macular Degeneration
Diabetic Macular Edema
Eligibility:
All Genders
50+ years
Brief Summary
This prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept. Ocular perfusion will be measured by L...
Eligibility Criteria
Inclusion
- age \> 50 years,
- patients scheduled for an intravitreal injections with Aflibercept for treatment of DME or AMD.
Exclusion
- ocular surgery (including intravitreal injection) during the 3 months preceding the study
- Ametropia \> 6 Dpt
- any relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. glaucoma, optic nerve head drusen, tilted disc, etc.).
Key Trial Info
Start Date :
November 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06878573
Start Date
November 22 2023
End Date
July 30 2024
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department for Ophthalmology
Linz, Upper Austria, Austria, 4020